Evidence map›Paper›PMID 25135070›Full record

ArticleMalaria journal2014

A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.

Rosalynn L Ord, Jerri C Caldeira, Marilis Rodriguez, Amy Noe, Bryce Chackerian, David S Peabody, Gabriel Gutierrez, Cheryl A Lobo

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. TargetingiScience · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Monoclonal antibodies for malaria prevention.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  13. Article
  14. Article
  15. Computational Clues of Immunogenic Hotspots inBioMed research international · 2022
    Article
  16. RNA Phage VLP-Based Vaccine Platforms.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rosalynn L Ord
Jerri C Caldeira
Marilis Rodriguez
Amy Noe
Bryce Chackerian
David S Peabody
Gabriel Gutierrez
Cheryl A LoboDepartment of Blood-Borne Parasites, New York Blood Center, New York, NY 10065, USA. CLobo@nybloodcenter.org.
New York Blood Center · USUniversity of New Mexico · USLeidos (United States) · US

Funding

AIDS VACCINE EVALUATION UNITSN01AI045210 · NIAID · VANDERBILT UNIVERSITY · PI WRIGHT, PETER F · 1994 to 2000
$114k
NIAID NIH HHS AI-N01-045210
6 · The paper itself

Abstract

backgroundThe Plasmodium falciparum protein RH5 is an adhesin molecule essential for parasite invasion of erythrocytes. Recent studies show that anti-PfRH5 sera have potent invasion-inhibiting activities, supporting the idea that the PfRH5 antigen could form the basis of a vaccine. Therefore, epitopes recognized by neutralizing anti-PfRH5 antibodies could themselves be effective vaccine immunogens if presented in a sufficiently immunogenic fashion. However, the exact regions within PfRH5 that are targets of this invasion-inhibitory activity have yet to be identified.

methodsA battery of anti-RH5 monoclonal antibodies (mAbs) were produced and screened for their potency by inhibition of invasion assays in vitro. Using an anti-RH5 mAb that completely inhibited invasion as the selecting mAb, affinity-selection using random sequence peptide libraries displayed on virus-like particles of bacteriophage MS2 (MS2 VLPs) was performed. VLPs were sequenced to identify the specific peptide epitopes they encoded and used to raise specific antisera that was in turn tested for inhibition of invasion.

resultsThree anti-RH5 monoclonals (0.1 mg/mL) were able to inhibit invasion in vitro by >95%. Affinity-selection with one of these mAbs yielded a VLP which yielded a peptide whose sequence is identical to a portion of PfRH5 itself. The VLP displaying the peptide binds strongly to the antibody, and in immunized animals elicits an anti-PfRH5 antibody response. The resulting antisera against the specific VLP inhibit parasite invasion of erythrocytes more than 90% in vitro.

conclusionsHere, data is presented from an anti-PfRH5 mAb that completely inhibits erythrocyte invasion by parasites in vitro, one of the few anti-malarial monoclonal antibodies reported to date that completely inhibits invasion with such potency, adding to other studies that highlight the potential of PfRH5 as a vaccine antigen. The specific neutralization sensitive epitope within RH5 has been identified, and antibodies against this epitope also elicit high anti-invasion activity, suggesting this epitope could form the basis of an effective vaccine against malaria.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ProtozoanCarrier ProteinsEpitope MappingEpitopesHumansMalaria, FalciparumMalaria VaccinesMiceNeutralization TestsPlasmodium falciparumAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ProtozoanCarrier ProteinsEpitopesMalaria VaccinesRH5 protein, Plasmodium falciparum

Identifiers

PMID25135070
PMCPMC4152569
OpenAlexW2144191305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.